Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction Academic Article uri icon

Overview

MeSH Major

  • Angioplasty
  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex

abstract

  • Aggressive platelet inhibition with abciximab during primary PTCA for acute MI yielded a substantial reduction in the acute (30-day) phase for death, reinfarction, and urgent target vessel revascularization. However, the bleeding rates were excessive, and the 6-month primary end point, which included elective revascularization, was not favorably affected.

publication date

  • August 15, 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9727542

Additional Document Info

start page

  • 734

end page

  • 41

volume

  • 98

number

  • 8